ES2175356T3 - Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares. - Google Patents

Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.

Info

Publication number
ES2175356T3
ES2175356T3 ES97907698T ES97907698T ES2175356T3 ES 2175356 T3 ES2175356 T3 ES 2175356T3 ES 97907698 T ES97907698 T ES 97907698T ES 97907698 T ES97907698 T ES 97907698T ES 2175356 T3 ES2175356 T3 ES 2175356T3
Authority
ES
Spain
Prior art keywords
disorders
dimetoxifenil
treatment
piperidinmetanol
fluorofenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907698T
Other languages
English (en)
Inventor
Cesare Mondadori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2175356T3 publication Critical patent/ES2175356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE (+) - AL - (2,3 DIMETOXIFENIL) - 1 - [2 - (4 - FLUOROFENIL)ETIL] - 4 PIPERIDINMETANOL EN EL TRATAMIENTO DE TRASTORNOS DEPRESIVOS O TRASTORNOS BIPOLARES.
ES97907698T 1996-03-21 1997-02-21 Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares. Expired - Lifetime ES2175356T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400591A EP0796619A1 (en) 1996-03-21 1996-03-21 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Publications (1)

Publication Number Publication Date
ES2175356T3 true ES2175356T3 (es) 2002-11-16

Family

ID=8225234

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907698T Expired - Lifetime ES2175356T3 (es) 1996-03-21 1997-02-21 Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.

Country Status (23)

Country Link
US (2) US6022877A (es)
EP (2) EP0796619A1 (es)
JP (1) JP4165906B2 (es)
KR (1) KR100423018B1 (es)
CN (1) CN1114406C (es)
AR (1) AR006281A1 (es)
AT (1) ATE219672T1 (es)
AU (1) AU704435B2 (es)
BR (1) BR9708109A (es)
CA (1) CA2250077C (es)
DE (1) DE69713571T2 (es)
DK (1) DK0888114T3 (es)
ES (1) ES2175356T3 (es)
HK (1) HK1019702A1 (es)
HU (1) HU226675B1 (es)
IL (1) IL126022A (es)
NO (2) NO316788B1 (es)
NZ (1) NZ331448A (es)
PT (1) PT888114E (es)
SI (1) SI0888114T1 (es)
TW (1) TW517048B (es)
WO (1) WO1997034603A1 (es)
ZA (1) ZA972345B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
PT1105132E (pt) * 1998-08-28 2004-02-27 Aventis Pharma Inc Utilizacao de r(+)-g(a)-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol para o tratamento da apneia obstrutiva do sono
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20020115695A1 (en) * 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
IL156460A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
EP2305645B1 (en) * 2008-06-20 2012-05-16 NHWA Pharma.corporation Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
DK0531410T3 (da) * 1990-06-01 1995-01-30 Merrell Dow Pharma (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
HUP9903684A3 (en) * 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
CA2250077C (en) 2003-10-07
JP4165906B2 (ja) 2008-10-15
TW517048B (en) 2003-01-11
HK1019702A1 (en) 2000-02-25
DK0888114T3 (da) 2002-10-07
NO316788B1 (no) 2004-05-10
KR20000064711A (ko) 2000-11-06
DE69713571D1 (de) 2002-08-01
NO20033184D0 (no) 2003-07-11
EP0796619A1 (en) 1997-09-24
AU704435B2 (en) 1999-04-22
US6022877A (en) 2000-02-08
AU1963197A (en) 1997-10-10
ATE219672T1 (de) 2002-07-15
NO984348L (no) 1998-09-18
EP0888114B1 (en) 2002-06-26
SI0888114T1 (en) 2002-10-31
HU226675B1 (en) 2009-06-29
JP2000506887A (ja) 2000-06-06
IL126022A0 (en) 1999-05-09
NZ331448A (en) 2000-06-23
NO984348D0 (no) 1998-09-18
AR006281A1 (es) 1999-08-11
CN1213968A (zh) 1999-04-14
WO1997034603A1 (en) 1997-09-25
DE69713571T2 (de) 2003-02-20
IL126022A (en) 2003-11-23
NO20033184L (no) 1998-09-18
CA2250077A1 (en) 1997-09-25
ZA972345B (en) 1997-09-25
CN1114406C (zh) 2003-07-16
KR100423018B1 (ko) 2004-05-17
US6380216B1 (en) 2002-04-30
BR9708109A (pt) 1999-07-27
EP0888114A1 (en) 1999-01-07
PT888114E (pt) 2002-11-29
HUP9902135A3 (en) 2001-05-28
HUP9902135A2 (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
NO20034056D0 (no) Proliferative sykdommer
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
IL164568A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
BG105256A (en) Muscarinic agonists and antagonists
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
TR200200278T2 (tr) Kalsilitik bileşimler
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
BG104914A (en) Paroxetine maleate
NO20005548L (no) Mykobakterieinhibitorer
TR199901385T2 (xx) Piperidin t�revleri.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 888114

Country of ref document: ES